MX375941B - Combinación de un fármaco quimioterapéutico y un fármaco de interferencia de netrina-1. - Google Patents

Combinación de un fármaco quimioterapéutico y un fármaco de interferencia de netrina-1.

Info

Publication number
MX375941B
MX375941B MX2015003343A MX2015003343A MX375941B MX 375941 B MX375941 B MX 375941B MX 2015003343 A MX2015003343 A MX 2015003343A MX 2015003343 A MX2015003343 A MX 2015003343A MX 375941 B MX375941 B MX 375941B
Authority
MX
Mexico
Prior art keywords
drug
netrin
combination
chemotherapeutic
interference
Prior art date
Application number
MX2015003343A
Other languages
English (en)
Other versions
MX2015003343A (es
Inventor
Andréa Paradisi
Pascale Nony
Patrick Mehlen
Original Assignee
Univ Claude Bernard Lyon
Centre Leon Berard
Centre Nat Rech Scient
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Claude Bernard Lyon, Centre Leon Berard, Centre Nat Rech Scient, Netris Pharma filed Critical Univ Claude Bernard Lyon
Publication of MX2015003343A publication Critical patent/MX2015003343A/es
Publication of MX375941B publication Critical patent/MX375941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un fármaco quimioterapéutico y un fármaco farmacéuticamente aceptable de interferencia de netrina-1 o un vector capaz de expresar un fármaco de interferencia de netrina-1 in vivo, en un portador o en un vehículo. El fármaco quimioterapéutico se selecciona de aquellos capaces de inducir la sobreexpresión de netrina-1 en células cancerosas. La combinación se asocia alefecto anticáncer sinérgico.
MX2015003343A 2012-09-12 2013-09-12 Combinación de un fármaco quimioterapéutico y un fármaco de interferencia de netrina-1. MX375941B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700158P 2012-09-12 2012-09-12
EP12306100.4A EP2708231A1 (en) 2012-09-12 2012-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
PCT/EP2013/068937 WO2014041088A2 (en) 2012-09-12 2013-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

Publications (2)

Publication Number Publication Date
MX2015003343A MX2015003343A (es) 2015-10-22
MX375941B true MX375941B (es) 2025-03-07

Family

ID=46924380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003343A MX375941B (es) 2012-09-12 2013-09-12 Combinación de un fármaco quimioterapéutico y un fármaco de interferencia de netrina-1.

Country Status (15)

Country Link
US (1) US9895439B2 (es)
EP (2) EP2708231A1 (es)
JP (1) JP6467604B2 (es)
KR (1) KR102424439B1 (es)
CN (2) CN110522913A (es)
AU (1) AU2013314320B2 (es)
BR (1) BR112015005443A2 (es)
CA (1) CA2884834C (es)
ES (1) ES2702733T3 (es)
HK (1) HK1208379A1 (es)
IL (1) IL237702B (es)
MX (1) MX375941B (es)
SG (1) SG11201501877WA (es)
WO (1) WO2014041088A2 (es)
ZA (1) ZA201502269B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN105031611B (zh) * 2015-06-18 2018-02-09 中国医学科学院基础医学研究所 netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途
AR106543A1 (es) 2015-11-02 2018-01-24 Netris Pharma Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
CN105861505A (zh) * 2016-05-31 2016-08-17 东北师范大学 靶向沉默UNC5A的shRNA
CA3045302A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
WO2018127570A1 (en) 2017-01-05 2018-07-12 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
AU2001293870A1 (en) 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human netrin binding membrane receptor unc5h-1
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
WO2005074556A2 (en) 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
US20080038255A1 (en) 2004-06-04 2008-02-14 Aplied Research Systems Ars Holding N.V. Splice Variant of Unc5h2
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
JP5089397B2 (ja) 2004-11-22 2012-12-05 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク 変異ネトリン４、その断片及びこれらの薬剤としての使用
US20060153840A1 (en) 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
KR101587932B1 (ko) 2006-02-28 2016-01-22 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크 네트린-1 활성을 이용한 항암 화합물의 스크리닝
WO2009141440A1 (en) 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
EP2208738A1 (en) * 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
MX2013001836A (es) 2010-08-26 2013-07-29 Hoffmann La Roche Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.

Also Published As

Publication number Publication date
WO2014041088A3 (en) 2014-07-03
EP2895173B1 (en) 2018-11-14
HK1208379A1 (en) 2016-03-04
EP2708231A1 (en) 2014-03-19
IL237702B (en) 2018-11-29
BR112015005443A2 (pt) 2017-12-05
JP6467604B2 (ja) 2019-02-13
KR20150079599A (ko) 2015-07-08
ZA201502269B (en) 2019-05-29
US20150246116A1 (en) 2015-09-03
KR102424439B1 (ko) 2022-07-21
AU2013314320B2 (en) 2017-04-06
CN104853756A (zh) 2015-08-19
US9895439B2 (en) 2018-02-20
JP2015529675A (ja) 2015-10-08
ES2702733T3 (es) 2019-03-05
SG11201501877WA (en) 2015-04-29
CN110522913A (zh) 2019-12-03
CA2884834A1 (en) 2014-03-20
AU2013314320A1 (en) 2015-04-02
CA2884834C (en) 2020-11-17
EP2895173A2 (en) 2015-07-22
WO2014041088A2 (en) 2014-03-20
AU2013314320A2 (en) 2015-04-09
MX2015003343A (es) 2015-10-22

Similar Documents

Publication Publication Date Title
MX375941B (es) Combinación de un fármaco quimioterapéutico y un fármaco de interferencia de netrina-1.
IL235020A0 (en) History of n-phenylbenzenesulfonamide, pharmaceutical preparations containing them and their use in the preparation of medicines
IL238476A0 (en) il-15r forms, cells expressing 15r-il forms and therapeutic uses of 15r-il alpha and 15r-il/15-il alpha complexes
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MY185016A (en) Progenitor cells of mesodermal lineage
IL239007A0 (en) Use of Aribolin to treat breast cancer
MX2016008448A (es) Conjugados de var2csa-farmaco.
AU348540S (en) Charging unit
MX2013004061A (es) Analogos de ciclosporina.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
AU348541S (en) Charging unit
MX2013004062A (es) Analogos de ciclosporina.
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
EP2658973A4 (en) SIRNA FOR INHIBITING HIF1A EXPRESSION AND ANTIBODIES THEREWITH
GEP201706742B (en) Glycogen-based water solubility enhancers
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
AU343145S (en) Desk
AU348538S (en) Charging unit
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EP2832353A4 (en) PHARMACEUTICAL COMPOSITION AND SOAP CAPSULE THEREWITH
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
EP2905284A4 (en) PHOTOSENSITIZATION TARGETING THYMIDINE KINASE AND PHARMACEUTICAL COMPOSITION AND USE FOR THE TREATMENT OF ASSOCIATED CANCER
UA78899U (uk) Лікувально-бандажний виріб

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: UNIVERSITE CLAUDE BERNARD LYON 1

FG Grant or registration